You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

primary central nervous system non-Hodgkin lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-hodgkin Lymphoma Trial (Methotrexate, Rituximab (where available), Ibrutinib)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • (no location specified)
Aug 11, 2023

Non-Hodgkin Lymphoma Trial in Cologne (Tafasitamab, Lenalidomide, Rituximab)

Not yet recruiting
  • Non-Hodgkin Lymphoma
  • Cologne, Germany
    University of Cologne
Oct 14, 2022

Lymphoma, Non-Hodgkin, CNS Tumors Trial in Trondheim (18F-FDG, 18F-fluciclovine, standard MRI)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Central Nervous System Neoplasms
  • 18F-FDG
  • +2 more
  • Trondheim, Norway
    Norwegian University of Science and Technology, Department of Ci
Dec 15, 2021

CNS B-Cell Non-Hodgkin Lymphoma Trial in United States (procedure, biological, other)

Recruiting
  • Central Nervous System B-Cell Non-Hodgkin Lymphoma
  • Cognitive Assessment
  • +2 more
  • Denver, Colorado
  • +11 more
Jun 9, 2022

Primary CNS Lymphoma, PCNSL, Non Hodgkin Lymphoma Trial in Guandong, Guangzhou (Methotrexate, Ibrutinib, Temozolomide)

Recruiting
  • Primary Central Nervous System Lymphoma
  • +2 more
  • Guandong, Guangdong, China
  • +2 more
Apr 6, 2022

Primary CNS Non-Hodgkin Lymphoma Trial in Cleveland (rituximab, yttrium Y 90 ibritumomab tiuxetan)

Terminated
Has Results
  • Primary Central Nervous System Non-Hodgkin Lymphoma
  • rituximab
  • yttrium Y 90 ibritumomab tiuxetan
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Jul 23, 2020

CNS B-Cell Non-Hodgkin Lymphoma, Recurrent CNS Lymphoma, Refractory CNS Lymphoma Trial in Houston (Ibrutinib, Nivolumab)

Recruiting
  • Central Nervous System B-Cell Non-Hodgkin Lymphoma
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 13, 2022

ALK-Positive Large B-Cell Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, DLBCL Activated B-Cell Type Trial in United

Active, not recruiting
  • ALK-Positive Large B-Cell Lymphoma
  • +34 more
  • Phoenix, Arizona
  • +32 more
Jan 3, 2023

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in

Active, not recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia
  • +125 more
  • tetanus-CMV fusion peptide vaccine
  • laboratory biomarker analysis
  • Duarte, California
    City of Hope Medical Center
Feb 28, 2022

Relapsed or Refractory (R/R) Primary CNS Lymphoma Trial in Nanjing (thiotepa combined with pomalidomide)

Recruiting
  • Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
  • thiotepa combined with pomalidomide
  • Nanjing, Jiangsu, China
    Jiangsu Province People's Hospital.
Jun 27, 2023

Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma Trial (intensity-modulated radiotherapy (IMRT))

Not yet recruiting
  • Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
  • intensity-modulated radiotherapy (IMRT)
  • (no location specified)
Jun 4, 2023

Non-hodgkin Lymphoma, B Cell Trial in Switzerland (ctDNA detection)

Not yet recruiting
  • Non-hodgkin Lymphoma, B Cell
  • ctDNA detection
  • Aarau, Switzerland
  • +12 more
Oct 18, 2023

Primary CNS Lymphoma Trial in Hangzhou (Rituximab, Lenalidomide, Methotrexate)

Completed
  • Primary Central Nervous System Lymphoma
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 18, 2022

Primary CNS Lymphoma Trial in Hanzhou (Orelabrutinib, Rituximab, Methotrexate)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Hanzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 3, 2022

Refractory CNS Lymphoma, Relapsed Primary CNS Lymphoma, Primary CNS Lymphoma Trial in Hangzhou (Nivolumab)

Active, not recruiting
  • Refractory Central Nervous System Lymphoma
  • +2 more
  • Hangzhou, Zhejiang, China
    Jianmin Zhang
Jul 3, 2022

Primary CNS Lymphoma, Secondary CNS Lymphoma, Relapsed Cancer Trial in Miami (drug, procedure, radiation)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • +3 more
  • Miami, Florida
    Miami Cancer Institute at Baptist Health, Inc.
Dec 23, 2022

Primary CNS Lymphoma Trial in Beijing (Camrelizumab)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Beijing, China
    Sanbo Brain Hospital Capital Medical University
Feb 10, 2022

Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in Beijing (GNC-038)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Beijing, Beijing, China
    Beijing Tiantan Hospital, Capital Medical University
Jul 31, 2022

CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma

Active, not recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • DISEASE
  • (no location specified)
May 4, 2023

Primary CNS Lymphoma Trial in Beijing (Orelabrutinib,Rituximab and Methotrexate)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Orelabrutinib,Rituximab and Methotrexate
  • Beijing, Beijing, China
    Hospital 307
Sep 19, 2022

Advanced Solid Tumors Harboring NTRK Fusion, Primary CNS Tumors Harboring NTRK Fusion Trial in Guangzhou (ICP-723)

Recruiting
  • Advanced Solid Tumors Harboring NTRK Fusion
  • Primary Central Nervous System Tumors Harboring NTRK Fusion
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Feb 16, 2023

Primary CNS Lymphoma Trial in Paris (Glucarpidase, Methotrexate (MTX))

Recruiting
  • Primary Central Nervous System Lymphoma
  • Paris, France
    Hôpital Pitié-Salpêtrière
Oct 24, 2022

Primary CNS Lymphoma Trial in Paris (PET-MRI)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • Paris, France
    Hôpital Pitié Salpêtrière
May 20, 2022

Primary CNS Lymphoma Trial in Shanghai (Orelabrutinib)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Shanghai, Shanghai, China
    Ruijin Hospital
Apr 18, 2022

CNS Lymphoma Trial in Aarhus (Immunochemo)

Completed
  • Central Nervous System Lymphoma
  • Aarhus, Denmark
    Elisa Jacobsen Pulczynski
Aug 3, 2022